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CORRESPONDENCE
Letters to the Editor
WATCHMAN for
Stroke Prevention:
An Out-of-Date Procedure
With interest we read the article by Sick et al. (1) about the
WATCHMAN left atrial appendage (LAA) system for stroke
prevention in atrial fibrillation (AF). We have concerns about the
rationale of this technique and questions about the results, which
prompt us to challenge the authors’ conclusion that LAA occlusion
with the WATCHMAN system is safe and effective.
First, there is no evidence that thromboembolism in AF
exclusively derives from LAA thrombi detected by transesophageal
echocardiography (TEE). When prospectively investigating clini-
cally stable outpatients with AF and no recent embolism by TEE,
the prevalence of LAA thrombi was only 2.5%, and during a
follow-up of 58 months, LAA thrombus did not predict stroke/
embolism (2).
Second, the LAA has properties that render device implantation
difficult and might impede patency of the occlusion. The LAA
myocardium has a higher distensibility than the left atrial myocar-
dium. This might induce oversizing of the device and lead to
compression of neighboring structures like the circumflex branch
of the left coronary artery (3). Progressive dilation of the LAA
occurs in AF, possibly leading to undersizing of the device and
leakage of a primarily completely closed LAA (3). Left atrial
appendage–endocardial fibroelastosis, occurring frequently in AF,
makes fixation of the device difficult. The LAA is a place of
secretion of atrial natriuretic peptide (ANP) (3). Possibly, contin-
uous ANP secretion into the LAA cavity even after closure might
contribute to leakages.
Third, incomplete LAA closure creates a pouch with stagnant
blood flow, which enhances thrombus formation and might
necessitate oral anticoagulation (OAC), although this was the
intention to prevent first. Thus, we cannot understand why
WATCHMAN placement was assessed as “successful” even in
cases with a jet 3 mm around the device. In how many patients
were small jets visible after implantation? And did the width of the
jets increase during follow-up? Were they associated with throm-
bus formation or embolism?
How many patients were screened altogether? What was the
kind and frequency of exclusion criteria? The listed comorbidities
are frequent in AF patients and would thus prompt OAC.
Were the patients investigated by a neurologist and cranial-
computed tomography or magnetic resonance imaging to look for
cerebral ischemia? Which was the indication for warfarin therapy
in 8% of the patients at 6-month follow-up?
It is reported that embolized devices were retrieved percutane-
ously. In the meantime, embolization of a WATCHMAN device
has been reported, which could be retrieved only by surgery, where
it was removed from the aortic valve and an aortic bioprosthesis
and a pacemaker had to be implanted (4).
Even if technical improvements would lead to a more effective
LAA occlusion, potential further side effects have to be considered.
The LAA plays an important role in hemodynamic and body fluid
regulation (3). Left atrial appendage elimination might impede
physiologic regulations of heart failure and thirst perception. The
ANP contributes to physiological control of lipid mobilization in
humans, whereas LAA elimination might promote development
of obesity (5). In view of global warming and the obesity epidemia,
LAA elimination has to be strongly questioned as a beneficial
procedure for stroke prevention in AF patients living in the 21st
century.
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Reply
Although we are pleased that Drs. Stöllberger and Finsterer read
our article with interest, their letter titled “An Out-of-Date-
Procedure” seems to be part of their series of editorials against left
atrial appendage (LAA) occlusion, made particularly odd in this
instance by the claim that use of these devices will contribute to the
obesity epidemic and global warming. We are also puzzled by the
characterization of this technology as “out of date,” considering
that it is currently undergoing its first randomized prospective trial.
Drs. Stöllberger and Finsterer state that they are prompted “to
challenge the authors’ conclusion that LAA occlusion with the
WATCHMAN system is safe and effective.” We are unable to
find any allusion to “safe and effective” in our report (1). Claims for
efficacy are not, as they might not be aware, designed into pilot
trials. Indeed we were careful to state that the study was not
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